If you follow EquipNet on Twitter, maybe you read an article we recently linked to titled, “Canada hands Osiris historic approval for stem-cell drug.” The article was about Canadian authorities giving Osiris the stamp of approval for Prochymal, which is the first drug in the world that has a stem cell as its active ingredient. It is designed to help children who have graft versus host disease.
This is great news for Osiris, but not all pharmaceutical companies are so lucky. Often, pharmaceutical companies invest millions of dollars in state-of-the-art lab and analytical equipment to design and test a new drug; however, if the drug fails to receive regulatory approval, the company may have no choice but to shut down the lab. Other reasons for a lab closure could include funding withdrawal or a shift of the company’s focus away from the drug being tested in that particular lab. With so much invested in a pharmaceutical lab, in the event of a closure, the company should take care to deal with the valuable assets inside in a way that best benefits the company as a whole. If your company is facing a lab closure, EquipNet has experience helping both global companies and small firms make good decisions about their valuable equipment, and we can help you do the same. Check out our Lab Closure Resource Center for more information.
If you are not yet following us on Twitter, please do. We regularly update our followers on new company information, and link to articles we think those in the pharmaceutical, chemical, and consumer goods manufacturing industries would find useful. We’d love to see you there!